Due to the rarity of the disease, adverse events related to ejaculatory function following the management of paratesticular rhabdomyosarcoma (ptRMS) with multi-modal therapy in adolescents are rarely discussed. Two patients, age 14 and 15 at time of diagnosis were treated with multi-modal therapy with nerve-sparing retroperitoneal lymph node dissection (NS-RPLND), chemotherapy, and radiotherapy. Each developed ejaculatory dysfunction during the treatment period, which resolved 1 year after completion of all therapies. We sought to assess the role of each component of multi-modal therapy on the observed side effect and the potential for delayed recovery of function after cessation of all therapies.
Urology. 2018 Oct 23 [Epub ahead of print]
James Rague, Briony K Varda, Andrew A Wagner, Richard S Lee
Boston Medical Center, Department of Urology, Boston, MA., Boston Children's Hospital, Department of Urology, Boston, MA., Beth Israel Deaconess Medical Center, Department of Urology, Boston, MA; Harvard Medical School, Department of Surgery, Boston, MA., Boston Children's Hospital, Department of Urology, Boston, MA; Harvard Medical School, Department of Surgery, Boston, MA. Electronic address: .